-
公开(公告)号：US07776329B2
公开(公告)日：2010-08-17
申请号：US10583795
申请日：2005-07-08
申请人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
发明人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
摘要： An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
-
公开(公告)号：US07919086B2
公开(公告)日：2011-04-05
申请号：US10583795
申请日：2005-07-08
申请人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
发明人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
CPC分类号： C07K16/28 , C07K7/06 , C07K14/47 , C07K16/303 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
摘要翻译： 公开了能够结合磷脂酰肌醇蛋白聚糖3的特定区域的抗体以及基于该抗体产生的人源化抗体。 本发明的抗GPC3抗体与常规抗体相比具有较高的ADCC活性和CDC活性。 本发明的抗体可用作细胞生长抑制剂，抗癌剂和癌症诊断剂。
-
公开(公告)号：US20070190599A1
公开(公告)日：2007-08-16
申请号：US10583795
申请日：2005-07-08
申请人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
发明人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
CPC分类号： C07K16/28 , C07K7/06 , C07K14/47 , C07K16/303 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
摘要翻译： 公开了能够结合磷脂酰肌醇蛋白聚糖3的特定区域的抗体以及基于该抗体产生的人源化抗体。 本发明的抗GPC3抗体与常规抗体相比具有较高的ADCC活性和CDC活性。 本发明的抗体可用作细胞生长抑制剂，抗癌剂和癌症诊断剂。
-
公开(公告)号：US20100248359A1
公开(公告)日：2010-09-30
申请号：US12797349
申请日：2010-06-09
申请人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
发明人： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
CPC分类号： C07K16/28 , C07K7/06 , C07K14/47 , C07K16/303 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
摘要翻译： 公开了能够结合磷脂酰肌醇蛋白聚糖3的特定区域的抗体以及基于该抗体产生的人源化抗体。 本发明的抗GPC3抗体与常规抗体相比具有较高的ADCC活性和CDC活性。 本发明的抗体可用作细胞生长抑制剂，抗癌剂和癌症诊断剂。
-
公开(公告)号：US20110033452A1
公开(公告)日：2011-02-10
申请号：US12852950
申请日：2010-08-09
申请人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
发明人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08 , C12N5/071 , A61P35/00
CPC分类号： C07K16/303 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/732
摘要： An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
摘要翻译： 提供了具有修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体，更具体地，提供了缺乏岩藻糖的磷脂酰肌醇蛋白聚糖3抗体。 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体可以通过包括将编码抗磷脂酰肌醇蛋白聚糖3抗体的核酸引入具有降低的岩藻糖加成能力的宿主细胞中的方法来生产，例如YB2 / 0细胞和缺乏细胞的细胞 岩藻糖转运蛋白 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体具有高水平的细胞毒活性，因此可用作细胞生长抑制剂如抗癌剂。
-
公开(公告)号：US20080124330A1
公开(公告)日：2008-05-29
申请号：US11577944
申请日：2005-10-26
申请人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
发明人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
IPC分类号： A61K39/395 , C07K16/18 , A61P43/00 , C12P21/04
CPC分类号： C07K16/303 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/732
摘要： An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
摘要翻译： 提供了具有修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体，更具体地，提供了缺乏岩藻糖的磷脂酰肌醇蛋白聚糖3抗体。 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体可以通过包括将编码抗磷脂酰肌醇蛋白聚糖3抗体的核酸引入具有降低的岩藻糖加成能力的宿主细胞中的方法来生产，例如YB2 / 0细胞和缺乏细胞的细胞 岩藻糖转运蛋白 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体具有高水平的细胞毒活性，因此可用作细胞生长抑制剂如抗癌剂。
-
公开(公告)号：US07867734B2
公开(公告)日：2011-01-11
申请号：US11577944
申请日：2005-10-26
申请人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
发明人： Kiyotaka Nakano , Izumi Sugo , Masamichi Sugimoto , Takahiro Ishiguro , Megumi Tanaka , Shigeyuki Iijima
CPC分类号： C07K16/303 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/732
摘要： An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
摘要翻译： 提供了具有修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体，更具体地，提供了缺乏岩藻糖的磷脂酰肌醇蛋白聚糖3抗体。 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体可以通过包括将编码抗磷脂酰肌醇蛋白聚糖3抗体的核酸引入具有降低的岩藻糖加成能力的宿主细胞中的方法来生产，例如YB2 / 0细胞和缺乏细胞的细胞 岩藻糖转运蛋白 具有本发明的修饰的糖链的磷脂酰肌醇蛋白聚糖3抗体具有高水平的细胞毒活性，因此可用作细胞生长抑制剂如抗癌剂。
-
8.发明申请公开(公告)号：US20100092457A1
公开(公告)日：2010-04-15
申请号：US12308695
申请日：2007-08-14
IPC分类号： A61K39/395 , C07K16/18 , C12N5/00 , C12Q1/68 , A61P35/00
CPC分类号： C07K16/28 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/30 , G01N33/57423 , G01N2333/705
摘要： Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
摘要翻译： 公开了涉及检测用于诊断癌症的DSG3蛋白的方法。 在肺癌中，发现DSG3的表达在基因水平和蛋白质水平上以非常高的频率增强。 本发明的方法可以使用识别DSG3蛋白质的抗体进行。 还公开了含有DSG3结合抗体作为活性成分的药物组合物，细胞生长抑制剂和抗癌剂。 还公开了在DSG3表达细胞中诱导细胞损伤的方法和通过使DSG3表达细胞与DSG3结合抗体接触来抑制表达DSG3的细胞增殖的方法。
-
公开(公告)号：US07993642B2
公开(公告)日：2011-08-09
申请号：US10551504
申请日：2004-12-10
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00
CPC分类号： C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/75
摘要： Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
摘要翻译： 分离纯化抗人Mpl抗体。 使用遗传工程技术制备抗人Mpl双抗体和抗人Mpl sc（Fv）2，抗人Mpl sc（Fv）2也被人源化。 测定双抗体和sc（Fv）2的TPO样激动活性，发现其活性高于抗人Mpl抗体的活性，或与天然存在的人TPO配体相当或更高的活性。
-
公开(公告)号：US08008073B2
公开(公告)日：2011-08-30
申请号：US12874872
申请日：2010-09-02
CPC分类号： C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/75
摘要： Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
摘要翻译： 分离纯化抗人Mpl抗体。 使用遗传工程技术制备抗人Mpl双抗体和抗人Mpl sc（Fv）2，抗人Mpl sc（Fv）2也被人源化。 测定双抗体和sc（Fv）2的TPO样激动活性，发现其活性高于抗人Mpl抗体的活性，或与天然存在的人TPO配体相当或更高的活性。
-
-
-
-
-
-
-
-
-
搜索结果
135 条记录 (耗时 0.043 秒)